|View printer-friendly version|
BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results
- To Submit New Drug Applications (“NDAs”) in
- To Submit NDAs in
“During the second quarter, we continued to demonstrate Plinabulin’s favorable drug profile for the treatment of NSCLC and CIN,” said
“In the near term, we expect to continue to generate additional data for Plinabulin in both NSCLC and CIN indications to support NDA filings in
Select Second-Quarter 2019 and Recent Highlights
Study 105 (Intermediate-Risk Chemotherapy)
Study 106 (High-Risk Chemotherapy)
Mechanism of Action
In June and
Financial Results for the Three Months Ended
Research and development (“R&D”) expenses were
General and administrative (“G&A”) expenses were
Net loss attributable to the Company was
The following outlines the Company's key anticipated upcoming milestones and projected timelines.
Conference Call and Webcast Information
BeyondSpring’s management will host a conference call and webcast today at 8:00 a.m. Eastern Time to discuss the financial results and provide a corporate update. The dial-in numbers for the conference call are 1-877-451-6152 (U.S.) or 1-201-389-0879 (international). Please reference conference ID 13694411. A live webcast will be available on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section. An archived replay of the webcast will be available for 30 days.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," “potential,” “suggest,” "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Specifically, these forward-looking statements include, but are not limited to, statements relating to the Company’s ability to establish its lead asset, Plinabulin, as a potentially superior new therapy for the treatment of chemotherapy-induced neutropenia and ability to advance its Phase 3 non-small cell lung cancer trial and earlier-stage programs, the potential for development and marketing of its product candidates, ability to advance its pipeline of immuno-oncology therapies and research activities, the potential effectiveness of Plinabulin, the potential for Plinabulin to address limitations in the current standard of care, the timing of clinical trials, receipt of clinical data or regulatory filings of the Company’s product candidates, and the Company’s ability to continue as a going concern. Forward-looking statements are based on
Neulasta® is a registered trademark of
Source: BeyondSpring, Inc.